Cargando…

Antitumoral Activity of Molecular Hydrogen and Proton in the Treatment of Glioblastoma: An Atypical Pharmacology?

Antioxidants in cancer therapy have been a hot topic in the medical field for 20 years. Antioxidants are able to reduce the risk of cancer formation by neutralizing free radicals. Protons (H+) and molecular hydrogen (H2) interact in the cell and are essential in a wide variety of processes. The anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Rochette, Luc, Dogon, Geoffrey, Zeller, Marianne, Cottin, Yves, Vergely, Catherine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452570/
https://www.ncbi.nlm.nih.gov/pubmed/37626524
http://dx.doi.org/10.3390/brainsci13081168
_version_ 1785095702667329536
author Rochette, Luc
Dogon, Geoffrey
Zeller, Marianne
Cottin, Yves
Vergely, Catherine
author_facet Rochette, Luc
Dogon, Geoffrey
Zeller, Marianne
Cottin, Yves
Vergely, Catherine
author_sort Rochette, Luc
collection PubMed
description Antioxidants in cancer therapy have been a hot topic in the medical field for 20 years. Antioxidants are able to reduce the risk of cancer formation by neutralizing free radicals. Protons (H+) and molecular hydrogen (H2) interact in the cell and are essential in a wide variety of processes. The antioxidant, anti-inflammatory, and antiapoptotic effects of H2 have been studied in numerous experimental and clinical studies. Experimental data indicate that H2 is an antitumor agent in the treatment of glioblastoma (GBM). In vivo H2 inhalation could suppress the growth of GBM tumors, thereby extending the survival of mice with GBM. The sphere-forming ability of glioma cells was suppressed by hydrogen treatment. In addition, H2 treatment also suppressed the migration, invasion, and colony-forming ability of glioma cells. Proton therapy and proton beam radiotherapy offer some advantages over other modern conformal photon-based therapies when used in the treatment of central nervous system malignancies.
format Online
Article
Text
id pubmed-10452570
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-104525702023-08-26 Antitumoral Activity of Molecular Hydrogen and Proton in the Treatment of Glioblastoma: An Atypical Pharmacology? Rochette, Luc Dogon, Geoffrey Zeller, Marianne Cottin, Yves Vergely, Catherine Brain Sci Opinion Antioxidants in cancer therapy have been a hot topic in the medical field for 20 years. Antioxidants are able to reduce the risk of cancer formation by neutralizing free radicals. Protons (H+) and molecular hydrogen (H2) interact in the cell and are essential in a wide variety of processes. The antioxidant, anti-inflammatory, and antiapoptotic effects of H2 have been studied in numerous experimental and clinical studies. Experimental data indicate that H2 is an antitumor agent in the treatment of glioblastoma (GBM). In vivo H2 inhalation could suppress the growth of GBM tumors, thereby extending the survival of mice with GBM. The sphere-forming ability of glioma cells was suppressed by hydrogen treatment. In addition, H2 treatment also suppressed the migration, invasion, and colony-forming ability of glioma cells. Proton therapy and proton beam radiotherapy offer some advantages over other modern conformal photon-based therapies when used in the treatment of central nervous system malignancies. MDPI 2023-08-05 /pmc/articles/PMC10452570/ /pubmed/37626524 http://dx.doi.org/10.3390/brainsci13081168 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Opinion
Rochette, Luc
Dogon, Geoffrey
Zeller, Marianne
Cottin, Yves
Vergely, Catherine
Antitumoral Activity of Molecular Hydrogen and Proton in the Treatment of Glioblastoma: An Atypical Pharmacology?
title Antitumoral Activity of Molecular Hydrogen and Proton in the Treatment of Glioblastoma: An Atypical Pharmacology?
title_full Antitumoral Activity of Molecular Hydrogen and Proton in the Treatment of Glioblastoma: An Atypical Pharmacology?
title_fullStr Antitumoral Activity of Molecular Hydrogen and Proton in the Treatment of Glioblastoma: An Atypical Pharmacology?
title_full_unstemmed Antitumoral Activity of Molecular Hydrogen and Proton in the Treatment of Glioblastoma: An Atypical Pharmacology?
title_short Antitumoral Activity of Molecular Hydrogen and Proton in the Treatment of Glioblastoma: An Atypical Pharmacology?
title_sort antitumoral activity of molecular hydrogen and proton in the treatment of glioblastoma: an atypical pharmacology?
topic Opinion
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10452570/
https://www.ncbi.nlm.nih.gov/pubmed/37626524
http://dx.doi.org/10.3390/brainsci13081168
work_keys_str_mv AT rochetteluc antitumoralactivityofmolecularhydrogenandprotoninthetreatmentofglioblastomaanatypicalpharmacology
AT dogongeoffrey antitumoralactivityofmolecularhydrogenandprotoninthetreatmentofglioblastomaanatypicalpharmacology
AT zellermarianne antitumoralactivityofmolecularhydrogenandprotoninthetreatmentofglioblastomaanatypicalpharmacology
AT cottinyves antitumoralactivityofmolecularhydrogenandprotoninthetreatmentofglioblastomaanatypicalpharmacology
AT vergelycatherine antitumoralactivityofmolecularhydrogenandprotoninthetreatmentofglioblastomaanatypicalpharmacology